Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management.
Schaefer B, Tobiasch M, Wagner S, Glodny B, Tilg H, Wolf M, Zoller H.
Bone. 2022 Jan;154:116202. doi: 10.1016/j.bone.2021.116202. Epub 2021 Sep 15.
Neurologic conditions and disorders of uremic syndrome of chronic kidney disease: presentations, causes, and treatment strategies.
Hamed SA.
Expert Rev Clin Pharmacol. 2019 Jan;12(1):61-90. doi: 10.1080/17512433.2019.1555468. Epub 2019 Jan 11.
Parathyroid disease.
Wen HY, Schumacher HR Jr, Zhang LY.
Rheum Dis Clin North Am. 2010 Nov;36(4):647-64. doi: 10.1016/j.rdc.2010.09.002.
Endocrine myopathies.
Ruff RL, Weissmann J.
Neurol Clin. 1988 Aug;6(3):575-92.
Primary hyperparathyroidism.
Bilezikian JP, Cusano NE, Khan AA, Liu JM, Marcocci C, Bandeira F.
Nat Rev Dis Primers. 2016 May 19;2:16033. doi: 10.1038/nrdp.2016.33.
[Primary hyperparathyroidism].
Maruani G, Cornière N, Nicolet L, Baron S, Courbebaisse M, Renaud S, Houillier P.
Rev Med Interne. 2013 Oct;34(10):605-13. doi: 10.1016/j.revmed.2012.10.369. Epub 2012 Nov 26.
Myopathy in primary hyperparathyroidism.
Caplan RH, Bogart KC.
Wis Med J. 1974 Mar;73(3):S27-31.
Surgical therapy of patients with primary hyperparathyroidism: long-term benefits.
Wells SA Jr.
J Bone Miner Res. 1991 Oct;6 Suppl 2:S143-9; discussion S151-2. doi: 10.1002/jbmr.5650061429.
Endocrine myopathies.
Kendall-Taylor P, Turnbull DM.
Br Med J (Clin Res Ed). 1983 Sep 10;287(6394):705-8. doi: 10.1136/bmj.287.6394.705.
[Primary hyperparathyroidism].
Carnevale V, Romagnoli E, Pipino M, Scillitani A, D'Erasmo E, Minisola S, Mazzuoli G.
Clin Ter. 2005 Sep-Oct;156(5):211-26.
